08/15/23 7:30 AMNasdaq : SNOA low floatNational Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn AdvancedBOULDER, CO / ACCESSWIRE / August 15, 2023 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasalRHEA-AIneutral
08/10/23 4:15 PMNasdaq : SNOA earningslow floatSonoma Pharmaceuticals Reports First Fiscal Quarter 2024 Financial ResultsRevenue increased 6% in the first fiscal quarter compared to the same period last year, excluding a one-time event last yearMargins remained consistent year over year in an inflationary period, excluding the one-time eventSonoma continued to manage cash tightly, using only $0.3 million of cash inRHEA-AInegative
08/03/23 7:30 AMNasdaq : SNOA managementlow floatSonoma Pharmaceuticals Announces Appointment of Hye Jin Chung, M.D. to Scientific Advisory BoardBOULDER, CO / ACCESSWIRE / August 3, 2023 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasalRHEA-AIpositive
06/22/23 7:30 AMNasdaq : SNOA earningslow floatSonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2023 Financial ResultsRevenues increased 31% in Q4 2023 compared to Q4 2022Revenues increased 5% in FY 2023 compared to FY 2022Net loss improved 56% quarter over quarterNet loss minus non-cash and one-time expenses decreased 65% quarter over quarter and 26% year over yearBOULDER, CO / ACCESSWIRE / June 22, 2023 / SonomaRHEA-AIneutral
06/08/23 4:01 PMNasdaq : SNOA low floatSonoma Pharmaceuticals Introduces Next Generation Solution for Pulse Lavage Irrigation in the European UnionBOULDER, CO / ACCESSWIRE / June 8, 2023 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, dermatology, andRHEA-AIneutral
04/11/23 7:30 AMNasdaq : SNOA low floatSonoma Pharmaceuticals Introduces Podiacyn, an All Natural, Over-the-Counter Podiatry Product for Daily Foot CareSonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn ® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal careRHEA-AIvery positive
03/28/23 4:15 PMNasdaq : SNOA low floatSonoma Pharmaceuticals to Exhibit at Upcoming CPHI North America Conference in PhiladelphiaSonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care,RHEA-AIneutral
03/02/23 7:30 AMNasdaq : SNOA low floatSonoma Pharmaceuticals and MicroSafe Group Announce New EPA Claims and Green Seal Certification for Nanocyn(R) Hospital-Grade DisinfectantSonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn ® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care,RHEA-AIneutral
02/14/23 4:30 PMNasdaq : SNOA earningslow floatSonoma Pharmaceuticals Reports Third Quarter 2023 Financial ResultsCash burn of $717,000 for the quarter ended December 31, 2022, 68% less than prior quarter cash burn of $2,235,000 Revenues for three and nine months ended December 31, 2022 essentially flat with strong performance in international sales European revenues increased 51% for the quarter and 29% forRHEA-AIneutral
01/31/23 7:30 AMNasdaq : SNOA partnershiplow floatSonoma Pharmaceuticals Announces Partnership with Daewoong Pharmaceutical for Distribution of Primocyn Skin Care in South KoreaSonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including dermatology, eye, oral and nasalRHEA-AIvery positive